Abcam Stock Price, News & Analysis (OTCMKTS:ABCZF) C$22.25 0.00 (0.00%) (As of 12/8/2023 ET) Add Compare Share Share Today's RangeC$22.25▼C$22.2550-Day RangeC$22.00▼C$22.3052-Week RangeC$5.00▼C$23.80VolumeN/AAverage Volume2,659 shsMarket CapitalizationN/AP/E Ratio130.73Dividend Yield0.32%Price TargetN/A Stock AnalysisStock AnalysisChartFinancialsSEC FilingsShort InterestStock AnalysisChartFinancialsSEC FilingsShort Interest About Abcam Stock (OTCMKTS:ABCZF)Abcam plc, a life science company, focuses on identifying, developing, and distributing reagents and tools for scientific research, diagnostics, and drug discovery. The company's principal products include primary and secondary antibodies; conjugated antibodies and conjugation kits; singleplex immunoassays; proteins and peptides that include cytokines; edited cell lines and lysates; and various other products, including cellular activity kits, biochemicals, and cell signaling pathway tools. It serves scientists and researchers in academic institutions and research institutes, as well as in pharmaceutical, biotechnology, and diagnostics companies. The company has operations in the Americas, Europe, the Middle East, Africa, China, Japan, and rest of the Asia Pacific. It sells its products online. The company was incorporated in 1998 and is headquartered in Cambridge, the United Kingdom.Read More ABCZF Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart ABCZF Stock News HeadlinesJuly 13, 2022 | benzinga.comAbcam (OTC:ABCZF), Short Interest ReportJuly 12, 2022 | benzinga.comAbcam (OTC:ABCZF), Earnings Estimates, EPS, and RevenueDecember 10, 2023 | Autonomix (Ad)[Investor Alert] Potential Breakthrough Medical Tech Investment OpportunityAutonomix has patented technology that can detect and target nerve signals at an accuracy never seen before, a $100B opportunity. Now the team with almost $600M in exits is planning to list Autonomix on the Nasdaq. And you can invest in Autonomix ahead of their intended Nasdaq listing.* *Disclosure: This is a paid advertisement for Autonomix’s Regulation A+ Offering. Please read the offering circular at invest.autonomix.comMay 20, 2022 | uk.finance.yahoo.comWhich way now for the Abcam share price?See More Headlines Receive ABCZF Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Abcam and its competitors with MarketBeat's FREE daily newsletter. Email Address Industry, Sector and Symbol Stock ExchangeOTCMKTS Industry Biotechnology Sub-IndustryN/A SectorMedical Current SymbolOTCMKTS:ABCZF CUSIPN/A CIK1492074 Webabcam.com Phone441223696000FaxN/AEmployees1,760Year FoundedN/AProfitability EPS (Most Recent Fiscal Year)N/A Trailing P/E Ratio130.73 Forward P/E RatioN/A P/E GrowthN/ANet IncomeN/A Net MarginsN/A Pretax MarginN/A Return on EquityN/A Return on AssetsN/A Debt Debt-to-Equity RatioN/A Current RatioN/A Quick RatioN/A Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book ValueN/A Price / BookN/AMiscellaneous Outstanding SharesN/AFree FloatN/AMarket CapN/A OptionableNot Optionable BetaN/A The 10 Best AI Stocks to Own in 2024Wondering where to start (or end) with AI stocks? These 10 simple stocks can help investors build long-term wealth as artificial intelligence continues to grow into the future.Get This Free Report Key ExecutivesMr. Alan Thomas Hirzel BS (Age 55)M.B.A., M.S., CEO & Executive Director Comp: $1.19MMr. Michael Shaun Baldock B.A. (Age 59)CFO & Director Comp: $879.04kMarc Leigh Russell PerkinsGeneral Counsel & Company SecretaryEmma SceatsSenior Vice President of Sales & MarketingMr. Nick SkinnerSenior Vice President of Human ResourcesMs. Alejandra Solache Ph.D.Senior Vice President of Research & DevelopmentMr. John BakerSenior Vice President of Supply Chain & ManufacturingJuan Carlos SacristanSenior Vice President of Data & DigitalMore ExecutivesKey Competitors3SBioOTCMKTS:TRSBF60 Degrees PharmaceuticalsNASDAQ:SXTPWAdociaOTCMKTS:ADOIFAgentixOTCMKTS:AGTXAinosNASDAQ:AIMDWView All Competitors ABCZF Stock Analysis - Frequently Asked Questions How have ABCZF shares performed in 2023? Abcam's stock was trading at C$15.24 on January 1st, 2023. Since then, ABCZF shares have increased by 46.0% and is now trading at C$22.25. View the best growth stocks for 2023 here. Is Abcam a good dividend stock? Abcam (OTCMKTS:ABCZF) pays an annual dividend of C$0.07 per share and currently has a dividend yield of 1.93%. The dividend payout ratio is 42.48%. This payout ratio is at a healthy, sustainable level, below 75%. How do I buy shares of Abcam? Shares of ABCZF stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here. This page (OTCMKTS:ABCZF) was last updated on 12/10/2023 by MarketBeat.com Staff Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Abcam plc Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.